US 2017/0362318 A1 · COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Claims427

Dependent claims

Isolated nucleic acid having a nucleotide sequence that has at least 80% nucleic acid sequence identity to:

(a) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), and FIG. 8 (SEQ ID NO:
8);
(b) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide:
(d) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence show n in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8). lacking its associated signal peptide;
(e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO :3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
(f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(g) the complement of (a), (b), (c), (d), (e) or (f).

28 more elements

An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7).

26 more elements

An isolated polypeptide having:

(a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide sequence;
(c) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide sequence;
(d) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide sequence;
(e) an amino acid sequence encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7).

26 more elements

A TAHO binding organic molecule that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7).

26 more elements

A method of inhibiting the growth of a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, with an antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent that binds to said protein, or with an antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent that binds to said protein, wherein the binding of said antibody, oligopeptide or organic molecule, said antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent or said antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent to said protein thereby causes an inhibition of growth of said cell.

26 more elements

A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising administering to said mammal a therapeutically effective amount of an antibody, oligopeptide or organic molecule that binds to said protein, an antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent that binds to said protein, or an antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent that binds to said protein, wherein said binding thereby effectively treats said mammal.

26 more elements

A method of determining the presence of a protein in a sample suspected of containing said protein, wherein said protein has at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising exposing said sample to an antibody, oligopeptide or organic molecule that binds to said protein, and determining binding of said antibody, oligopeptide or organic molecule to said protein in said sample, wherein binding of the antibody, oligopeptide or organic molecule to said protein is indicative of the presence of said protein in said sample.

26 more elements

A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of said protein, thereby effectively treating or preventing said cell proliferative disorder.

26 more elements

A method of binding an antibody, oligopeptide or organic molecule to a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule, an antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent or an antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent that binds to said protein allowing the binding of said antibody, oligopeptide or organic molecule, said antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent or said antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent to said protein to occur, to said cell.

26 more elements

A method for inhibiting the growth of a cell, wherein the growth of said cell is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, an antibody, oligopeptide or organic molecule conjugated to a cytotoxic agent that binds to said protein, or an antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent, there by inhibiting the growth of said cell.

26 more elements

A method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6) and FIG. 8 (SEQ ID NO:
8), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5) and FIG. 7 (SEQ ID NO:
7), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, an antibody, oligopeptide or organic molecule conjugated to a cytotoxic toxin or an antibody, oligopeptide or organic molecule conjugated to a growth inhibitory agent, thereby effectively treating said tumor.

26 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/406,583Filed 13 Jan 2017

Priority

8 May 2002

Published

21 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6851
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a determinant of a…
A61P 35/00
Antineoplastic agents

Family

Application60/378,885Us provisional application · filed 8 May 2002

Application60/405,645Us provisional application · filed 21 Aug 2002

Application10/411,010Continuation in part · filed 10 Apr 2003

Application10/643,795Continuation in part · filed 19 Aug 2003

Application60/520,842Us provisional application · filed 17 Nov 2003

Application60/532,426Us provisional application · filed 24 Dec 2003

Application60/576,517Us provisional application · filed 1 Jun 2004

Application60/616,098Us provisional application · filed 5 Oct 2004

Application10/989,826Continuation in part · filed 16 Nov 2004

Application11/141,344Continuation in part · filed 31 May 2005

Application11/462,336Continuation in part · filed 3 Aug 2006

Application12/023,811Division · filed 31 Jan 2008

Application12/878,920Continuation · filed 9 Sep 2010

Application15/406,583Continuation

Application12/878,920Division

Application12/023,811Continuation in part

Application12/878,920Continuation in part

US 2003/0228319 A1Published application

US 2004/0241703 A1Published application

US 2005/0238650 A1Published application

US 2005/0276812 A1Published application

US 2007/0207142 A1Published application

US 2009/0068178 A1Published application

US 2011/0070243 A1Published application

US 2017/0362318 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Compositions and methods for the treatment of tumor hematopoietic origin

Life of this patent

Abstract

Claims427

Compositions and methods for the treatment of tumor hematopoietic origin

Life of this patent

Abstract

Claims427